DOCSLIB.ORG

Overview and Analysis of Harm Reduction Approaches and Services for Children and Young People Who Use Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overview and Analysis of Harm Reduction Approaches and Services for Children and Young People Who Use Drugs Overview and analysis of harm reduction approaches and services for Children and Young People Who Use Drugs Produced by Graham Shaw Consulting Ltd for the ICF “International HIV/AIDS Alliance in Ukraine” This material has been prepared within the Harm Reduction for children young people who use drugs in Ukraine: Reaching the Underserved, 2015. Project implemented with financial support from the Elton John AIDS Foundation. Copyright 2015 © ICF “International HIV/AIDS Alliance in Ukraine Acronyms AdjHR Adjusted Hazard Ratio(s) AFEW AIDS Foundation East-West AHR Adjusted Hazard Ratio AOR Adjusted Odds Ratio ART Antiretroviral Therapy ARYS At-Risk Youth Study ATS Amphetamine Type Stimulant(s) BBV Blood Borne Virus(es) BiH Bosnia and Herzegovina CBT Cognitive–Behavioural Therapy CEE Central and Eastern Europe CFA Confirmatory Factor Analysis CFI Comparative Fit Index CI Confidence Interval CIS Commonwealth of Independent States CISHRWIN Civil Society on Health & Right of Vulnerable Women and Girls in Nigeria CM Crystal Methamphetamine CPCS Child Protection Centres and Services CRC United Nations Convention on the Rights of the Child CYP Children and Young People CYPUD Children and Young People who Use Drugs DUST Drug Use Screening Tool EFA Exploratory Factor Analysis EHRN Eurasian Harm Reduction Network EMCDDA European Monitoring Centre for Drugs and Drug Addiction ESPAD European School Survey Project on Alcohol and Other Drugs EU European Union EVA Extremely Vulnerable Adolescent(s) EVYP Extremely Vulnerable Young People FFI Frequent Former Injector(s) FUS Frequency of Use Score HBV Hepatitis B virus HCP Health Care Practitioner HCV Hepatitis C virus HR Hazards Ratio(s) HRI Harm Reduction International (formerly IHRA, the International Harm Reduction Association) IATT Inter-Agency Task Team IAWG Inter-Agency Working Group IDPC International Drug Policy Consortium IDU Injecting Drug Use(r) IFI Infrequent Former Injector(s) IQR Interquartile Range IVDU Intravenous Drug Use(r) KP Key Population(s) LGBTQ Lesbian, Gay, Bisexual, Transgender and Queer LMICs Low and Middle Income Countries LSD Lysergic acid diethylamide, also known as lysergide and colloquially as 'acid' MA Methamphetamine 2 MARA Most-At-Risk Adolescent(s) MI Motivational Interviewing MSF Doctors Without Borders MSM Men who have Sex with Men NTASM National Treatment Agency for Substance Misuse (UK) NEP Needle Exchange Programme NGO Non-Governmental Organisation NIDU Non-Injecting Drug Use NIROA Non-Injecting Routes Of Administration NIU Non-Injecting Users NSP Needle and Syringe Programme OHCHR United Nations High Commissioner for Human Rights OR Odds Ratio(s) OST Opioid Substitution Therapy OTC Over The Counter PCB Programme Coordinating Board (of UNAIDS) PDS Polydrug Use Score PrEP Pre-Exposure Prophylaxis PSI Population Services International PWID People Who Inject Drugs PWUD People Who Use Drugs PYAR Person-Years-At-Risk RISE Resource, Information, Support, Education, as in the organisation Youth RISE RTI Route Transition Intervention SEE South East Europe SG Shooting Gallery SIBA Safer Interventions and Broader Acceptance SSS Sensation Seeking Scale STI Sexually Transmitted Infection TB Tuberculosis UK United Kingdom of Great Britain and Northern Ireland UN United Nations Organisation UNAIDS Joint United Nations Programme on HIV/AIDS UNCTs United Nations Country Teams UNFPA United Nations Population Fund UNICEF United Nations Children's Fund UNODC United Nations Office on Drugs and Crime UNSCR United Nations Security Council Resolution WHO World Health Organization WLDAS West Lothian Drug and Alcohol Service WMD Weighted Mean Difference YKP Young Key Populations YPWID Young People Who Inject Drugs 3 Contents Acronyms ................................................................................................................................................ 2 Preface .................................................................................................................................................... 5 Executive Summary ................................................................................................................................. 6 1. Introduction .................................................................................................................................. 8 1.1 How to use this report ........................................................................................................ 8 1.2 Definitions .......................................................................................................................... 9 2. Methodology .............................................................................................................................. 10 3. Analysis of studies of harm reduction for CYPUD....................................................................... 12 4. Analysis of methodologies, approaches and experiences in the delivery of harm reduction services in the Americas and Europe, including countries of the Former Soviet-Union, for CYPUD ......................................................................................................................................... 14 5. Analysis of data on existing harm reduction services for CYPUD ............................................... 24 6. Analysis of international experience on prevention of transition from non-injecting to injecting by CYPUD .................................................................................................................................... 28 ANNEX A References to studies of harm reduction for CYPUD ....................................................... 38 ANNEX B References to methodologies, approaches and experiences in the delivery of harm reduction services for CYPUD ..................................................................................................... 41 ANNEX C References to data for existing harm reduction services for CYPUD ............................... 84 ANNEX D References to international experience on prevention of transition from non-injecting to injecting by CYPUD ..................................................................................................................... 87 ANNEX E Harm reduction services for CYPUD ............................................................................... 128 Endnotes ............................................................................................................................................. 139 Table 1 Agencies identified that provide some form of drug use interventions for CYPUD aged 10-18 years 25 Figure 1 A schema for route transition interventions (RTIs) 34 4 Preface It is only in relatively recent years that harm reduction for children and young people who use drugs (CYPUD) has begun to see the light of day as a crucially important intervention for the continuum of prevention to care and treatment for communicable diseases, especially HIV/AIDS, tuberculosis and viral hepatitis. Although well intentioned, a lengthy period of time has been taken by international agencies, such as those in the United Nations - particularly UNICEF, UNAIDS, WHO and UNODC - and international NGOs, in discussing, debating and arguing over the age range and the terminology to be used for those who are not legally adults in their own country or territory. Whilst the legal basis for such health and related service interventions is important, it has somewhat distracted such well- meaning organisations from moving rapidly forward with specific guidance on how to assess the unique needs of CYPUD and how to establish and scale-up harm reduction services for such young members of the population. As with 'adults' who use, or inject, drugs, there can be multiple risk behaviours facing CYPUD including sex work, domestic violence which may, or may not, include sexual abuse, as well as young people/adolescents who are in the process of becoming aware of their sexual orientation and gender identity. Regardless of age or 'label' used to describe them, at-risk CYPUD cannot be protected from communicable diseases by simply waving legislation in the air that results in them being unable to access the health and related services that they need. Rather, practical steps that are evidence- based and implemented in a manner that is acceptable to the target populations within the CYPUD- community are needed, and urgently. And those interventions are already well known and referred to as 'harm reduction', of which global guidance has been available from WHO, UNODC and UNAIDS since 2007 (update in 2012). As Fisher notes, "it is not the substance use, but rather the physical, psychosocial, emotional, and often legal consequences of use that lead to terrible consequences among adolescents."1(1) Even with the advent of the UN Convention on the Rights of the Child (CRC), little practical progress has been made around the world in recognising, implementing, evaluating and taking to scale harm reduction interventions for CYPUD in direct violation of the CRC. Many articles published since the late 1990's cannot even bring themselves to consider harm reduction as a viable intervention for CYPUD, preferring instead to focus on drug use prevention and abstinence-based approaches, especially those in schools which, overall, have been an abject failure around the world. Although there have been many lessons learnt in the realm of drug demand reduction and drug use prevention that unanimously show that such approaches fail badly, there continues
Load more

Recommended publications
  • A Policy Perspective on the Global Use of Smokeless Tobacco
    Curr Addict Rep DOI 10.1007/s40429-017-0166-7 TOBACCO (AH WEINBERGER, SECTION EDITOR) A Policy Perspective on the Global Use of Smokeless Tobacco Kamran Siddiqi1 & Aishwarya Lakshmi Vidyasagaran1 & Anne Readshaw1 & Ray Croucher2 # The Author(s) 2017. This article is an open access publication Abstract Keywords Smokeless tobacco . Snus . Tobacco control . Background Globally, over 300 million people consume di- Global health verse smokeless tobacco (ST) products. They are addictive, cause cancer, increased cardiovascular mortality risks and poor pregnancy outcomes. Introduction Purpose of Review To identify gaps in implementing key ST demand-reduction measures, focused literature reviews were “Smokeless tobacco” (ST) comprises tobacco products that do conducted and findings synthesized according to relevant not involve a combustion process, such as chewing, nasal and WHO Framework Convention on Tobacco Control (FCTC) oral tobacco [1•]. Globally, over 300 million people consume Articles. ST [1•], yet ST has been largely neglected in research and Recent Findings The literature supports implementation of policy arenas because it is generally regarded as less harmful ST demand-reduction measures. For taxation, labelling and than cigarettes. It is also seen as a regional rather than a global packaging, most administrations have weaker policies for ST problem, and too diverse and complex to control. than cigarettes. Capacity to regulate ST contents and offer ST use is reported in at least 116 countries worldwide, cessation support is lacking. There is poor compliance with including countries in Africa, Asia, Europe and the bans on ST advertising, promotion and sponsorship. Americas [2•]. Smokeless tobacco consumption is therefore Summary The literature on implementation of WHO a global public health issue.
    [Show full text]
  • 2020 International Narcotics Control Strategy Report
    United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions ..............................................................................................................................
    [Show full text]
  • Finland Country Drug Report 2017
    Finland Country Drug Report 2017 Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 3) | Drug laws and drug law offences (p. 4) | Drug use (p. 5) | Drug harms (p. 8) | Prevention (p. 10) | Harm reduction (p. 11) | Treatment (p. 12) | Drug use and responses in prison (p. 14) | Quality assurance (p. 15) | Drug-related research (p. 15) | Drug markets (p. 16) | Key drug statistics for Finland (p. 18) | EU Dashboard (p. 20) THE DRUG PROBLEM IN FINLAND AT A GLANCE Drug use Treatment entrants Overdose deaths Drug law offences in young adults (15-34 years) by primary drug in the last year 250 Cannabis 200 23 478 166 150 13.5 % Top 5 drugs seized 100 ranked according to quantities Cannabis, 21% 50 measured in kilograms Amphetamines, 15 % Cocaine, 0 % 0 1. Amphetamine 2011 2012 2013 2015 2014 Opioids, 52 % 2010 2007 2008 2006 9 % 17.9 % 2009 Other, 12 % 2. Herbal cannabis Other drugs Opioid substitution HIV diagnoses 3. Cannabis resin MDMA 2.5 % treatment clients attributed to injecting 4. Cocaine Amphetamines 2.4 % 14 5. Heroin Cocaine 1 % 12 3 000 10 Population 8 (15-64 years) 6 7 High-risk opioid users Syringes distributeddistributed 4 through specialised 2 3 483 757 programmes 0 13 836 2011 2012 2013 2015 2014 2010 2007 2008 2006 2009 Source: EUROSTAT (12 700 - 15 090) 5 301 000 Source: ECDC Extracted on: 26/03/2017 NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures).
    [Show full text]
  • DEMAND REDUCTION a Glossary of Terms
    UNITED NATIONS PUBLICATION Sales No. E.00.XI.9 ISBN: 92-1-148129-5 ACKNOWLEDGEMENTS This document was prepared by the: United Nations International Drug Control Programme (UNDCP), Vienna, Austria, in consultation with the Commonwealth of Health and Aged Care, Australia, and the informal international reference group. ii Contents Page Foreword . xi Demand reduction: A glossary of terms . 1 Abstinence . 1 Abuse . 1 Abuse liability . 2 Action research . 2 Addiction, addict . 2 Administration (method of) . 3 Adverse drug reaction . 4 Advice services . 4 Advocacy . 4 Agonist . 4 AIDS . 5 Al-Anon . 5 Alcohol . 5 Alcoholics Anonymous (AA) . 6 Alternatives to drug use . 6 Amfetamine . 6 Amotivational syndrome . 6 Amphetamine . 6 Amyl nitrate . 8 Analgesic . 8 iii Page Antagonist . 8 Anti-anxiety drug . 8 Antidepressant . 8 Backloading . 9 Bad trip . 9 Barbiturate . 9 Benzodiazepine . 10 Blood-borne virus . 10 Brief intervention . 11 Buprenorphine . 11 Caffeine . 12 Cannabis . 12 Chasing . 13 Cocaine . 13 Coca leaves . 14 Coca paste . 14 Cold turkey . 14 Community empowerment . 15 Co-morbidity . 15 Comprehensive Multidisciplinary Outline of Future Activities in Drug Abuse Control (CMO) . 15 Controlled substance . 15 Counselling and psychotherapy . 16 Court diversion . 16 Crash . 16 Cross-dependence . 17 Cross-tolerance . 17 Custody diversion . 17 Dance drug . 18 Decriminalization or depenalization . 18 Demand . 18 iv Page Demand reduction . 19 Dependence, dependence syndrome . 19 Dependence liability . 20 Depressant . 20 Designer drug . 20 Detoxification . 20 Diacetylmorphine/Diamorphine . 21 Diuretic . 21 Drug . 21 Drug abuse . 22 Drug abuse-related harm . 22 Drug abuse-related problem . 22 Drug policy . 23 Drug seeking . 23 Drug substitution . 23 Drug testing . 24 Drug use .
    [Show full text]
  • Neotrance and the Psychedelic Festival DC
    Neotrance and the Psychedelic Festival GRAHAM ST JOHN UNIVERSITY OF REGINA, UNIVERSITY OF QUEENSLAND Abstract !is article explores the religio-spiritual characteristics of psytrance (psychedelic trance), attending speci"cally to the characteristics of what I call neotrance apparent within the contemporary trance event, the countercultural inheritance of the “tribal” psytrance festival, and the dramatizing of participants’ “ultimate concerns” within the festival framework. An exploration of the psychedelic festival offers insights on ecstatic (self- transcendent), performative (self-expressive) and re!exive (conscious alternative) trajectories within psytrance music culture. I address this dynamic with reference to Portugal’s Boom Festival. Keywords psytrance, neotrance, psychedelic festival, trance states, religion, new spirituality, liminality, neotribe Figure 1: Main Floor, Boom Festival 2008, Portugal – Photo by jakob kolar www.jacomedia.net As electronic dance music cultures (EDMCs) flourish in the global present, their relig- ious and/or spiritual character have become common subjects of exploration for scholars of religion, music and culture.1 This article addresses the religio-spiritual Dancecult: Journal of Electronic Dance Music Culture 1(1) 2009, 35-64 + Dancecult ISSN 1947-5403 ©2009 Dancecult http://www.dancecult.net/ DC Journal of Electronic Dance Music Culture – DOI 10.12801/1947-5403.2009.01.01.03 + D DC –C 36 Dancecult: Journal of Electronic Dance Music Culture • vol 1 no 1 characteristics of psytrance (psychedelic trance), attending specifically to the charac- teristics of the contemporary trance event which I call neotrance, the countercultural inheritance of the “tribal” psytrance festival, and the dramatizing of participants’ “ul- timate concerns” within the framework of the “visionary” music festival.
    [Show full text]
  • Framework Convention on Tobacco Control (WHO FCTC) Is the First Treaty Negotiated Under the Auspices of the World Health Organization
    World Health Organization Geneva, Switzerland WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL World Health Organization WHO Library Cataloguing-in-Publication Data WHO Framework Convention on Tobacco Control. 1.Tobacco - supply and distribution 2.Tobacco industry - legislation 3.Tobacco smoke pollution - prevention and control 4.Tobacco use cessation 5.Treaties I.World Health Organization. ISBN 92 4 159101 3 (LC/NLM classification: HD 9130.6) © World Health Organization 2003, updated reprint 2004, 2005 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • COVID and Beyond Dart RC Opioid Abuse
    Trends within Drug Abuse and Healthcare – COVID and Beyond Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Safety, Denver Health Executive Director, RADARS® System Professor, University of Colorado School of Medicine Competing Interests RADARS® System is the property of The Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. RADARS® System is supported by subscriptions from pharmaceutical manufacturers, government and nongovernment agencies for surveillance, research, and reporting services. No subscriber participated in the conception, analysis, drafting, or review of this presentation. 2 3 What Caused the US Opioid Crisis - HHS • In the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to opioid pain relievers and health care providers began to prescribe them at greater rates. • Increased prescription of opioid medications led to widespread misuse of both prescription and non-prescription opioids before it came clear that these medications could indeed be highly addictive. • 2017 HHS declared a public health emergency and announced a five point strategy to combat the opioid crisis https://www.hhs.gov/opioids/about-the-epidemic/index.html 4 What Really Happened? • Health care systems and regulation • Fifth vital sign, patient “satisfaction,” etc. • Careless doctors • We knew better, but let convenience win out. • Criminal behavior • Opioid marketing • Aggressive, irresponsible • Increased supply of illicit opioids • Lack of treatment for OUD • Good, but after the fact, insufficient to meet demand • Increased demand? 5 What Happened to Rx Drug Abuse? 10 Years ago… Prescription drug abuse is the Nation's fastest-growing drug problem, and the Centers for Disease Control and Prevention has classified prescription drug abuse as an epidemic.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Inner Visions: Sacred Plants, Art and Spirituality
    AM 9:31 2 12/10/14 2 224926_Covers_DEC10.indd INNER VISIONS: SACRED PLANTS, ART AND SPIRITUALITY Brauer Museum of Art • Valparaiso University Vision 12: Three Types of Sorcerers Gouache on paper, 12 x 16 inches. 1989 Pablo Amaringo 224926_Covers_DEC10.indd 3 12/10/14 9:31 AM 3 224926_Text_Dec12.indd 3 12/12/14 11:42 AM Inner Visions: Sacred Plants, Art and Spirituality • An Exhibition of Art Presented by the Brauer Museum • Curated by Luis Eduardo Luna 4 224926_Text.indd 4 12/9/14 10:00 PM Contents 6 From the Director Gregg Hertzlieb 9 Introduction Robert Sirko 13 Inner Visions: Sacred Plants, Art and Spirituality Luis Eduardo Luna 29 Encountering Other Worlds, Amazonian and Biblical Richard E. DeMaris 35 The Artist and the Shaman: Seen and Unseen Worlds Robert Sirko 73 Exhibition Listing 5 224926_Text.indd 5 12/9/14 10:00 PM From the Director In this Brauer Museum of Art exhibition and accompanying other than earthly existence. Additionally, while some objects publication, expertly curated by the noted scholar Luis Eduardo may be culture specific in their references and nature, they are Luna, we explore the complex and enigmatic topic of the also broadly influential on many levels to, say, contemporary ritual use of sacred plants to achieve visionary states of mind. American and European subcultures, as well as to contemporary Working as a team, Luna, Valparaiso University Associate artistic practices in general. Professor of Art Robert Sirko, Valparaiso University Professor We at the Brauer Museum of Art wish to thank the Richard E. DeMaris and the Brauer Museum staff present following individuals and agencies for making this exhibition our efforts of examining visual products arising from the possible: the Brauer Museum of Art’s Brauer Endowment, ingestion of these sacred plants and brews such as ayahuasca.
    [Show full text]
  • Civil Society Monitoring of Harm Reduction in Europe, 2019
    Correlation Correlation European DATA REPORT Eropean Harm Reduction R C Network C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 1 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 ® Correlation – European Harm Reduction Network, 2019. This publication of Correlation – European Harm Reduction Network is protected by copyright. Reproduction is authorised provided the source is acknowledged. Recommended citation: Tammi, T., Rigoni, R., Matičič, M., Schäffer, D., van der Gouwe, D., Schiffer, K., Perez Gayo, R., Schatz, E. (2020): Civil Society Monitoring of Harm Reduction in Europe, 2019. Data Report. Correlation European Harm Reduction Network, Amsterdam. Correlation – European Harm Reduction Network c/o Foundation De REGENBOOG GROEP Droogbak 1d 1013 GE Amsterdam The Netherlands www.correlation-net.org This project has been supported by the European Commission. Correlation - European Harm Reduction Network is co-funded by the European Union 2 Correlation European DATA REPORT Harm Reduction C Network CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 DATA REPORT 3 CIVIL SOCIETY MONITORING OF HARM REDUCTION IN EUROPE, 2019 CONTRIBUTORS Editor: The data network: Graham Shaw Albania: Genci Mucollari, Aksion Plus Austria: Alexandra Karden & Barbara Siokola, Scientific expert group: Suchthilfe Wien Tuukka Tammi (THL), Dagmar Hedrich (EMCDDA), Belgium: Peter Blanckaert & Tessa Windelinckx, Sam Shirley-Beavan (HRI), Perrine Roux (INSERM). Free Clinic Bosnia and Herzegovina: Samir Ibisevic, PROI
    [Show full text]
  • The Impact of Drug Policy on Women
    THE IMPACT OF DRUG POLICY ON WOMEN Kasia Malinowska-Sempruch & Olga Rychkova As member states of the United Nations take stock of the 02 INTRODUCTION drug control system, a number of debates have emerged among governments about how to balance international 03 WHAT THE UN AND OTHER INTERNATIONAL BODIES SAY drug laws with human rights, public health, alternatives to incarceration, and experimentation with regulation. 07 ISSUES RELEVANT TO UNGASS DEBATES This series intends to provide a primer on why governments 18 CONCLUSIONS AND RECOMMENDATIONS must not turn a blind eye to pressing human rights and public health impacts of current drug policies. 01 THE IMPACT OF DRUG POLICY ON WOMEN WHAT IS THE IMPACT OF DRUG POLICY ON WOMEN? “Who ever heard of a female drug lord? As the terms ‘kingpin’ and ‘drug lord’ denote, men are almost always at the head of major drug operations, and yet the rate of imprisonment of women for drug crimes has far outpaced that of men. Families and children suffer—but why?” –American Civil Liberties Union et al., Caught in the Net, 2005 1 1 American Civil Liberties Union (ACLU), Breaking the Chains and Brennan Center for Justice. Caught in the net: the impact of drug policies on women and families. New York, 2005. At: https://www.aclu.org/drug-law-reform/caught-net-impact-drug-policies-women-and-families. 02 THE IMPACT OF DRUG POLICY ON WOMEN INTRODUCTION In the public mind, the “war on drugs” probably conjures up a male image. In most countries, official statistics would show that men, indeed, are the majority of people who use drugs recreationally, who have problematic use, and who sell drugs.
    [Show full text]
  • Research Chemicals Und Andere Neue Drogen
    Research Chemicals & andere „neue“ Drogen Impulsreferat auf der DO-Leitertagung am 08.04.2014 Dipl.-Psych. Marcus Breuer psycholog. Psychotherapeut Begriffsklärung • Crystal = Crystal Speed; kristallines Metamphetamin • ATS = Amphetamin Type Stimulants • NPS = New Psychoactive Substances • Badesalze = Szenebezeichnung, denkbar ungeeignet, weil sie nichts erklärt und außerdem verharmlost • Research Chemicals = diese Stoffe sind „Abfallprodukte“ aus der Medikamentenentwicklung oder aber gezielte Veränderungen bekannter psychoaktiver Substanzen • Legal Highs = viele dieser neuen Stoffe sind bzw. waren zunächst legal (nicht dem BtmG unterstellt) • Kräutermischungen = Spice & Co., rauchbare synthetische Cannabinoide (viel toxischer als Cannabis) Wirkbogen der Partydrogen Entaktogene Ecstasy-MDMA MDEE Häufigkeit • ATS= Amphetamine Type Stimulants • Amphetamin (Speed) • XTC (MDMA; MDE; MDA) • Methamphetamin (Crystal) • Weltweit zusammen 26 million “regular users” vs: • Kokain 14 million reg. users • Heroin 16 million reg. users Nach WHO and UNODOC-Schätzungen (2010) ist Methamphetamin weltweit alleine die nach CANNABIS am häufigsten konsumierte illegale Substanz(18 Mio) (Nikotin und Alkohol sind Hauptproblem…..) Gesamtzahlen erstauffällige Konsumenten nach BKA: Trend 2000-2009 Drogentrends Exkurs: Research Chemicals I Neue Clubdrugs/Trenddrogen - fast alles RC-Drugs: • Substanzen, die zu Forschungszwecken genutzt werden und als solche „gekauft“ werden…. • RC-Substanzen (research chemicals) / Designerdrugs….. • Zeitweise nicht dem BTMG der jeweiligen
    [Show full text]